Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 18 04:00PM ET
Dollar change
Percentage change
CategoryUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsU.S. Return% 1Y5.37% Shs Outstand Perf Week-2.74%
SponsorVirtus ETF Solutions ETF Type Tagsequity Return% 3Y2.69% Total Holdings66 Perf Month1.69%
Fund Family Bond Type Tagshealthcare Return% 5Y8.64% AUM20.20M Perf Quarter1.69%
IndexLifeSci Biotechnology Products Index Average Maturity Tagsbiotechnology Return% 10Y NAV% Perf Half Y-0.27%
Index Weighting Commodity Type Tags- Return% SI NAV/sh Perf Year4.74%
Active/Passive Quant Type Tags- Flows% 1M0.00% 52W Range45.00 - 63.25 Perf YTD-1.75%
Dividend TTM- ESG Type Tags- Flows% 3M0.00% 52W High-9.76% Beta0.63
Dividend Ex-DateDec 20, 2017 Dividend Type Sector/Theme Flows% YTD17.79% 52W Low26.83% ATR (14)0.62
Expense0.79% Structure Type Region Flows% 1Y RSI (14)49.49 Volatility0.34% 0.48%
Option/ShortYes / No Growth/Value Dev/Emerg Flows% 3Y Rel Volume2.59 Prev Close57.71
Inverse/Leveraged Market Cap Currency Flows% 5Y Avg Volume1.14K Price57.07
SMA20-0.58% SMA503.11% SMA2004.99% Trades Volume2,957 Change-1.10%
Virtus LifeSci Biotech Products ETF seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.